Skip to main content

Market Overview

Corbus Pharmaceuticals: Q3 Earnings Insights

Share:

 

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.6% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share fell 34.37% year over year to ($0.43), which missed the estimate of ($0.42).

Revenue of $1,231,000 decreased by 52.47% from the same period last year, which missed the estimate of $2,310,000.

Outlook

Corbus Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 10, 2020

Time: 08:30 AM

ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/crbp/mediaframe/41687/indexl.html

Technicals

Company's 52-week high was at $9.78

52-week low: $0.91

Price action over last quarter: down 81.85%

Company Description

Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

 

Related Articles (CRBP)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com